ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy

Contributed by: PR Newswire

Tags

ERA-Congress-Study

More Like This

Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress

Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy

Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th International Symposium on IgA Nephropathy (IIgANN) Tokyo 2023

Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis

Calliditas Therapeutics to Present Nefecon Data at the 17th International Symposium on IgA Nephropathy (IIgANN) September 25-27 in Tokyo

Positive data from phase 2 NOBLE study of pegcetacoplan presented as late-breaker at ERA congress

Calliditas Announces Positive NefIgArd Open Label Extension Results

The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine